The Battle Royale Between Oncologists and Payers in Implementing Precision Oncology
Russell “Russ” Ingersoll, PhD, Chief Product Officer, Trapelo; Debra Patt, MD, PhD, MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives, Texas Oncology
Precision medicine is changing the way cancer is tested and treated in the US, but a lack of standardization and barriers to collaboration between oncologists, payers and genomic testing labs has been slowing its use. In fact, the gap between how oncologists and payers make oncology care decisions has never been greater, and it is impeding the application of life-saving therapies.
This “battle royale” between payers and oncologists must end to ensure cancer patients are getting the most appropriate precision testing and therapies at the right stage of their treatment journeys. But how? Join Dr. Debra Patt, M.D., MBA, PH.D., Health Economics and Health Services Research Oncologist and breast cancer expert at Texas Oncology and Russell Ingersoll, Ph.D. Chief Product Officer and pharmacology and toxicology expert at Trapelo Health for an in-depth discussion on the root causes, how we can bring stakeholders together and create a more modern prior authorization process that brings the right therapy to cancer patients more quickly.